1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

Anew Medical Receives Patents for Genetic Therapy of AD and ALS

12 Aug 2024
Admin
News Article

Anew Medical Receives Patents for Genetic Therapy of AD and ALS

Anew Medical receives patents in major Asian markets for use of genetic therapy to treat Alzheimer's disease and ALS

Overview

Anew Medical, Inc., a US-based biotechnology company focused on developing cell- and gene-based treatments to affect aging and age-related diseases, announces the grant and issuance of patent number HK1259628 protecting the development of novel genetic approaches for the treatment of neurodegenerative diseases to include Alzheimer’s disease, Parkinson’s diseases and amyotrophic lateral sclerosis (ALS).

Previous Announcements from the Company

The company previously announced that it had been granted this key patent in China (Patent No. CN 117126829A) for the use of Anew’s Klotho protein and Klotho gene delivery and expression systems in the treatment of cognition, memory and neurodegenerative diseases.
This intellectual property was licensed by Anew from Universitat Autònoma DE Barcelona (UAB) and Institució Catalana DE Recerca I Estudis Avançats (ICREA) in Barcelona, Spain on an exclusive worldwide basis.

Words from the CEO: Anew

Dr Joseph Sinkule, the founder and CEO of Anew, stated: “With intellectual property protection in Hong Kong, Beijing, Shanghai, and throughout the Chinese market for our innovative way of treating neurodegenerative diseases like Alzheimer’s diseases (AD), identifying clinical trial sites and corporate partners to evaluate the efficacy and safety of our product candidates is very important to Anew.”
Dr Sinkule continued: “The patents, comprising the secreted form of the human Klotho protein (s-KL) being delivered as a protein or by delivery of a sequence of the human gene that makes the protein in the body, are projected to be a major advance in how we treat or prevent the progression of these neurologic diseases. We are particularly excited about the preclinical results and plan to begin human testing in late 2025.”

Alzheimer's Patients Around the Globe

The aging population in China is affected by the same age-related diseases we are fighting in the US and Europe.
According to a recent report, China has the highest number of Alzheimer's patients in the world, with nearly 10 million people aged 60 and older suffering from the disease.
Additionally, Asia in general is experiencing the fastest growth in the elderly population is taking place.
Japan is considered a “super-aging” country, and the number of people with AD in Japan is expected to reach approximately 6.5–7 million by 2025, very similar to the prevalence of AD in the US (approximately 7 million cases).
AD and AD-associated dementia are very common in Western Europe and Finland, with North America following close behind.
While AD is least common in Sub-Saharan Africa, African-Americans in the US are about twice as likely to have Alzheimer's disease or other forms of dementia as Caucasian and Hispanic Americans.

About Anew Medical

Anew Medical, Inc. is a biopharmaceutical company specializes in the development of patented, novel disease-modifying technologies targeting the brain and central nervous system (CNS) that are seen as key developments in treating neurodegenerative and age-related disorders.